Literature DB >> 7849308

Interleukin-6 in human multiple myeloma.

B Klein1, X G Zhang, Z Y Lu, R Bataille.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7849308

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  96 in total

1.  Syndrome of inappropriate antidiuretic hormone due to multiple myeloma.

Authors:  Ashley Abraham; Fariha Shafi; Maaz Iqbal; Ramya Kollipara; Emran Rouf
Journal:  Mo Med       Date:  2011 Sep-Oct

2.  An intermediate-risk multiple myeloma subgroup is defined by sIL-6r: levels synergistically increase with incidence of SNP rs2228145 and 1q21 amplification.

Authors:  Owen W Stephens; Qing Zhang; Pingping Qu; Yiming Zhou; Shweta Chavan; Erming Tian; David R Williams; Joshua Epstein; Bart Barlogie; John D Shaughnessy
Journal:  Blood       Date:  2011-11-09       Impact factor: 22.113

Review 3.  Divide and conquer: the importance of cell division in regulating B-cell responses.

Authors:  Stuart G Tangye; Philip D Hodgkin
Journal:  Immunology       Date:  2004-08       Impact factor: 7.397

4.  Adaptation to survival in germinal center is the initial step in onset of indolent stage of multiple myeloma.

Authors:  Ariosto S Silva; Robert A Gatenby
Journal:  Mol Pharm       Date:  2011-10-12       Impact factor: 4.939

5.  γ-Tocotrienol but not γ-tocopherol blocks STAT3 cell signaling pathway through induction of protein-tyrosine phosphatase SHP-1 and sensitizes tumor cells to chemotherapeutic agents.

Authors:  Ramaswamy Kannappan; Vivek R Yadav; Bharat B Aggarwal
Journal:  J Biol Chem       Date:  2010-08-18       Impact factor: 5.157

6.  Isoliquiritigenin inhibits the growth of multiple myeloma via blocking IL-6 signaling.

Authors:  Xiangzheng Chen; Yangping Wu; Yangfu Jiang; Yan Zhou; Yuxi Wang; Yuqin Yao; Cheng Yi; Lantu Gou; Jinliang Yang
Journal:  J Mol Med (Berl)       Date:  2012-05-31       Impact factor: 4.599

Review 7.  Treatment of multiple myeloma in elderly patients. New developments.

Authors:  G J Ossenkoppele
Journal:  Drugs Aging       Date:  1997-08       Impact factor: 3.923

8.  Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140 mg/m2 of melphalan in multiple myeloma: results of a pilot study including biological aspects.

Authors:  J-F Rossi; N Fegueux; Z Y Lu; E Legouffe; C Exbrayat; M-C Bozonnat; R Navarro; E Lopez; P Quittet; J-P Daures; V Rouillé; T Kanouni; J Widjenes; B Klein
Journal:  Bone Marrow Transplant       Date:  2005-11       Impact factor: 5.483

9.  IL-6 and MYC collaborate in plasma cell tumor formation in mice.

Authors:  Sebastian Rutsch; Vishala T Neppalli; Dong-Mi Shin; Wendy DuBois; Herbert C Morse; Hartmut Goldschmidt; Siegfried Janz
Journal:  Blood       Date:  2009-12-17       Impact factor: 22.113

10.  Fas/Fas ligand (FasL)-deregulated apoptosis and IL-6 insensitivity in highly malignant myeloma cells.

Authors:  M A Frassanito; F Silvestris; N Silvestris; P Cafforio; G Camarda; G Iodice; F Dammacco
Journal:  Clin Exp Immunol       Date:  1998-11       Impact factor: 4.330
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.